Skip to main content

Blood Loss, Surgical

3
Pipeline Programs
9
Companies
8
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

9 companies ranked by most advanced pipeline stage

VarmX
VarmXNetherlands - Leiden
1 program
1
VMX-C001Phase 31 trial
Active Trials
NCT07288489Recruiting800Est. Jan 2031
CSL Seqirus
CSL SeqirusUK - Maidenhead
1 program
1
Haemate HSPhase 2
Becton Dickinson
Becton DickinsonFRANKLIN LAKES, NJ
1 program
1
AristaPhase 12 trials
Active Trials
NCT06822036Recruiting362Est. Jan 2027
NCT05522153Completed61Est. Jun 2023
Defence Therapeutics
Defence TherapeuticsBC - Vancouver
1 program
Measurement of external blood lossN/A1 trial
Active Trials
NCT05316649Unknown45Est. Aug 2022
Artivion
ArtivionKENNESAW, GA
1 program
PerClot Polysaccharide Hemostatic SystemN/A1 trial
Active Trials
NCT02359994Completed324Est. Feb 2019
SPARK Biopharma
SPARK BiopharmaKorea - Seoul
1 program
Volta tAN SystemN/A1 trial
Active Trials
NCT06647017Recruiting40Est. Nov 2026
Spark Biomedical
Spark BiomedicalTX - Dallas
1 program
Volta tAN SystemN/A
Hemorai
HemoraiAR - Bentonville
1 program
Wearable optical hemodynamic monitoring deviceN/A1 trial
Active Trials
NCT07826637Not Yet Recruiting80Est. Sep 2027
CSL Behring
CSL BehringIL - Bradley
1 program
Haemate HSPHASE_21 trial
Active Trials
NCT00618293Withdrawn0Est. Jul 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
VarmXVMX-C001
CSL BehringHaemate HS
Becton DickinsonArista
HemoraiWearable optical hemodynamic monitoring device
Becton DickinsonArista
SPARK BiopharmaVolta tAN System
Defence TherapeuticsMeasurement of external blood loss
ArtivionPerClot Polysaccharide Hemostatic System

Clinical Trials (8)

Total enrollment: 1,712 patients across 8 trials

NCT07288489VarmXVMX-C001

Phase 3 Trial of VMX-C001 vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.

Start: Aug 2026Est. completion: Jan 2031800 patients
Phase 3Recruiting
NCT00618293CSL BehringHaemate HS

Haemate HS in Patients With Severe Bleeding Undergoing Valve Replacement Due to Aortic Stenosis

Start: Jan 2008Est. completion: Jul 20110
Phase 2Withdrawn
NCT05522153Becton DickinsonArista

Arista Hemostatic Powder for Total Knee Post Operative Outcomes Study

Start: May 2021Est. completion: Jun 202361 patients
Phase 1Completed
NCT07826637HemoraiWearable optical hemodynamic monitoring device

Study of the Hemorai Vysio Wearable Device for Monitoring Changes Related to Blood Loss in Patients During and After Surgery.

Start: Oct 2026Est. completion: Sep 202780 patients
N/ANot Yet Recruiting
NCT06822036Becton DickinsonArista

EFFICACY OF INTRAOPERATIVE ARISTA POLYSACCHARIDE APPLICATION ON THE POSTOPERATIVE BLOOD LOSS IN PATIENTS UNDERGOING RARP FOR THE TREATMENT OF PROSTATE CANCER

Start: Jan 2025Est. completion: Jan 2027362 patients
N/ARecruiting
NCT06647017SPARK BiopharmaVolta tAN System

Delivering Transcutaneous Auricular Neurostimulation to Reduce Blood Loss During Dialysis AV Graft Placement Procedures

Start: Nov 2024Est. completion: Nov 202640 patients
N/ARecruiting
NCT05316649Defence TherapeuticsMeasurement of external blood loss

Blood Loss Quantification During Major Abdominal Surgery

Start: May 2021Est. completion: Aug 202245 patients
N/AUnknown
NCT02359994ArtivionPerClot Polysaccharide Hemostatic System

Prospective, Multicenter, Multidisciplinary, Controlled Clinical Investigation Evaluating the Safety and Efficacy of PerClot® Polysaccharide Hemostatic System

Start: Apr 2015Est. completion: Feb 2019324 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
3 actively recruiting trials targeting 1,712 patients
9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.